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Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-
102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer.
Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from
the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of
these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.
1. Introduction
Increased survival of metastatic gastric cancer (GC) is still
an unmet clinical need. Generally, the first line of treatment
is represented by a combination of chemotherapy with plat-
inum and fluoropyrimidine with or without a third drug [1].
After progression of disease from first line, taxanes (mainly
paclitaxel) and irinotecan have been shown to be effective and
tolerable [2], while ramucirumab, a human IgG1 monoclonal
antibody against vascular endothelial growth factor receptor
2 (VEGFR2), alone or in combination with paclitaxel has
statistically increased survival for GC patients [3, 4].
Unfortunately, no clear evidence has been established for
patients who experience disease progression after a second
line of therapy. In particular, no randomised, prospective
clinical trial or guideline has supported the use of a specific
drug. Recently, this scenario seems changed as novel agents
have been shown to increase survival in third or in a
further line of treatment. Based on the positive results of
two randomized trials against placebo, apatinib, a small
selective VEGFR2 tyrosine kinase inhibitor, has been the
first to demonstrate a survival advantage in this GC patient
population and from 2014 is approved in China [5]. In
addition, nivolumab, a fully human IgG4 monoclonal anti-
body inhibitor of programmed death-1 (PD-1), also showed
a survival benefit compared with placebo in patients with
advanced gastric cancer refractory to two or more pre-
vious regimens of chemotherapy [6], and more recently,
trifluridine/tipiracil, a novel oral combination cytotoxic drug
also known as TAS-102, has significantly improved overall
survival (OS) compared with placebo in heavily pretreated
population of patients with advanced gastric cancer [7]. The
purpose of this review is to briefly summarize the results of
the studies with these novel drugs focusing on some limits
that might at least in part reside in their clinical relevance.
1.1. Apatinib. Apatinib is a small-molecule receptor tyrosine
kinase inhibitor that primarily binds to and inhibits VEGFR2
[5]. In addition, this agent inhibits c-Kit and c-SRC tyrosine
kinases at higher concentrations [5]. In 2013, Li et al. con-
ducted a phase II, randomized, double-blinded, and placebo-
controlled trial to evaluate the efficacy and safety of daily
apatinib administration as third-line treatment in patients
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affected by metastatic GC [8]. The study was conducted at
15 hospitals in China with a total of 141 patients enrolled and
randomly assigned to receive placebo (groupA, number=48),
apatinib 850 mg once daily (group B, number=47), or
apatinib 425 mg twice daily (group C, number=46). Apatinib
demonstrated improved OS and progression-free survival
(PFS) in heavily pretreated patients with metastatic GC who
underwent two or more previous chemotherapy regimens’
failure. The median OS was significantly higher in patients
treated with apatinib versus those given a placebo with a
median OS of 2.50 months for patients in group A, 4.83
months for patients in group B, and 4.27 months for patients
in group C. Also, the PFS was significantly higher in patients
administered with apatinib than in placebo with a median
PFS of 1.40months for group A, 3.20months for group B, and
3.67 months for group C. As a noteworthy event, 9 patients
(3 treated with apatinib 850mg and 6 treated with apatinib
425mg) had a partial response confirmed on computer
tomography scan and 43% of patients given apatinib reached
disease control.
In 2016, Li et al. performed a randomized, double-blind,
placebo-controlled phase III trial to evaluate the efficacy
and safety of apatinib in patients with advanced metastatic
gastric cancer or gastroesophageal junction adenocarcinoma,
refractory to two or more lines of previous chemotherapy
regimens [9]. The study was undertaken in 32 centres in
China and involved 267 patients randomly assigned at a
2:1 ratio to receive apatinib-matching placebo tablets once
daily (number=91) or oral apatinib 850 mg in tablet form
(number=176). This phase III study reported that apatinib,
administered asmonotherapy, prolonged OS and PFS: the OS
was 6.5 months for the apatinib group and 4.7 months for the
placebo group; likewise, the PFS improved from 1.8 months
in the placebo group to 2.6 months in the apatinib group.
In addition, the objective response rate (ORR) achieved was
2.84%with apatinib and 0%with placebo whereas the disease
control rate (DCR) was critically higher in the apatinib
group (42.05%) compared to the placebo group (8.79%).
Unfortunately, no significant differences between the two
groups with regard to the quality of life have been reported.
In addition, dose reduction resulting from toxicity was more
common in the apatinib group mainly due to grade 3 to
4 hand-foot skin reaction (8.5%), proteinuria (2,3%), and
hypertension (4.5%).
In 2017, Ruan et al. carried out a multicenter, open-label,
single-arm phase II study to evaluate the safety and efficacy
of apatinib in patients affected by metastatic GC [10]. They
enrolled a total of 42 patients from 4 different institutions
in China with a histologically confirmed metastatic GC
diagnosis, with no previous molecular target therapy but a
second-line or last chemotherapy regimen failure. All patients
were administered with apatinib 850 mg daily 30 minutes
postprandially on days 1 to 28 of each 4-week cycle. They
clearly demonstrated that apatinib is safe and with good
efficacy in pretreated metastatic GC patients as the median
PFS and OS reported were 4.0 months (95% CI, 2.8-5.1)
and 4.5 months (95% CI, 4.0-4.9), respectively. The disease
control rate and objective response rate were 78.6% and
9.5% after 2 cycles and 57.1% and 19.0% after 4 cycles.
They also showed that toxicities were tolerable and clinically
manageable with elevated aminotransferase (45.2%), hand-
foot syndrome (40.5%), and secondary hypertension (35.7%)
as main adverse events. Up to date, no planned study will
investigate the role of Apatinib in non-Asian patients and in
third or further line of treatment.
1.2. Nivolumab. Nivolumab is a fully human IgG4 mono-
clonal antibody known as a programmed cell death 1 (PD-
1) immune checkpoint inhibitor. PD-1 is a transmembrane
inhibitory immune-receptor, member of the B7-CD28 family,
expressed on activated T, B, and natural killer cells [11].
Kang et al. assessed the safety and efficacy of nivolumab in
493 patients with advanced gastric or gastroesophageal junc-
tion cancer intolerant of, or refractory to, two or more previ-
ous regimens of chemotherapy in the randomised, placebo-
controlled, double-blinded, phase III ATTRACTION-2 [6].
The study was performed at 49 hospitals in Taiwan, South
Korea, and Japan and the 493 patients were randomly
assigned at a ratio 2:1 to receive 3mg/kg of nivolumab (n=330)
or placebo (n=163) intravenously every 2 weeks; patients who
had previously been treated with anti-PD-L1 or anti-PD-L2,
anti-PD-1, anti-CD137, or anti-CTLA4 were excluded from
the trial. The primary endpoint of the study was OS. Patients
in the nivolumab group had longer survival of 5.26 months
compared to the placebo group with 4.14 months. The risk
of disease progression was lower in nivolumab group (46%)
than the placebo group (60%) and 11.2% of patients in the
nivolumab group had an objective response (all confirmed
partial responses) in comparison to a 0% in the placebo
group. In addition, 29.1% of patients in the nivolumab arm
achieved stable disease compared to the 25.2% of the placebo
arm; thus the percentage of patients with disease control
was 40% in the nivolumab group and 25% in the placebo
group. Interestingly, two subgroup analyses indicated that
nivolumab improved OS regardless of PD-L1 positivity and
previous ramucirumab treatment. Although symptomatic
adverse events were reported equally in both groups and the
incidence of serious treatment-related adverse events was low
(mainly pruritus, diarrhoea, rash, and fatigue), a limitation
of this study was the absence of data about the quality
of life. A subsequent analysis from the ATTRACTION-2
showed a similar OS improvement of Nivolumab compared
to placebo in the Japanese subpopulation [12]. In addition,
data from the gastric cohort from the multicenter, phase
I/II CheckMate-032 [13] trial demonstrated a clinical activity
of nivolumab and nivolumab plus ipilimumab in patients
with chemotherapy-refractory esophagogastric cancer; how-
ever, phase III studies are awaited to confirm these data.
Finally, although several studies are investigating the role of
nivolumab in GC, no other studies are planned in third or
further line of therapy.
1.3. Trifluridine/Tipiracil. TAS-102 is a novel oral cytotoxic
chemotherapy consisting of a combination of trifluridine:
thymidine-based nucleoside analogue and tipiracil: a thymi-
dine phosphorylase inhibitor. For this reason, TAS-102 has a
unique mechanism of action [14, 15].
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In 2016, Bando et al. performed a multicenter, phase II,
single arm, open-label study to assess the safety, pharmacoki-
netic, and efficacy profile of TAS-102 single therapy in patients
affected by advanced GC [6]. Six Japanese institutions and
a total of 29 patients were involved in this clinical trial.
All patients were > 19 years old, affected by unresectable
or recurrent oesophagogastric junction or gastric adenocar-
cinoma with one or two previous chemotherapy regimens
containing platinum derivatives, irinotecan, taxanes or flu-
oropyrimidine, and a documented progression of disease;
the ECOG performance status score was 0 to 2 organ
functions reasonable. Patients received a 35mg/m2 twice oral
dose (b.i.d.) of TAS-102 per day after meals during a 28-d
schedule with treatment on days 1-5 and 8-12. The 35 mg/m2
b.i.d. dose of TAS-102 showed efficacy with no unexpected
toxicity in advanced GC patients and the primary point–the
disease control rate–has been achieved and exceeded the
primary endpoint target. The investigator determined dis-
ease control rate was 65.5% (95% confidence interval, 45.7-
82.1%) whereas the independent central review’s disease
control rate was 51.9% (95% CI, 31.9-71.3%); the median
PFS and OS were, respectively, 2.9 months (95% CI, 1.1-
5.3 months) and 8.7 months (95% CI, 5,7.14.9 months).
Neutropenia (69.0%), leucopenia (41.4%), anaemia (20.7%),
and anorexia (10.3%) were the main grade III/IV adverse
events reported.
In 2018, Shitara et al. [7] reported the results of a ran-
domised, multinational, double-blinded, placebo-controlled,
and phase III trial to assess the efficacy and safety of trifluri-
dine/tipiracil at the dose of 35 mg/m2 twice daily on days 1–5
and days 8–12 every 28 days plus best supportive care as a new
option treatment in patients heavily pretreated and affected
bymetastatic GC. OSwas the primary endpoint.The trial was
carried out in 110 academic hospitals of 17 countries, enrolling
a total of 507 patients randomly assigned at a 2:1 ratio to the
TAS-102 group (number=337) and the placebo group (num-
ber=170). A survival benefit was noted with TAS-102: the OS
was 5.7 months in the TAS-102 group and 3.6 months in
the placebo group; the disease progression at the data cut-off
occurred in 85% of patients in the TAS-102 group and in 92%
of patients in the placebo group; 14%of patients in the placebo
group and 44% of patients in the TAS-102 group achieved an
acceptable disease control. TAS-102 was well-tolerated even
though a dosage modification due to an any-grade adverse
event of any cause was reported in 22% of patients in the
placebo group and in 58% in the trifluridine/tipiracil group.
A potential limitation of the study was the scheduling of
the first tumour assessment performed 8 weeks later after
the randomisation, which might have precluded detection
of radiological progression at earlier time points and the
absence of data of patients pretreated with ramucirumab.
Finally, quality of life data were investigated but were not
reported as they will be in a separate paper. Interestingly,
the NCT03686488 study is recruiting patients to evaluate the
combination of TAS 102 and ramucirumab in patients with
advanced, refractory gastric, or gastroesophageal junction
adenocarcinoma and the phase I/II trial (NCT03368963) will
investigate the combination of TAS-102 with nanoliposomal
irinotecan in patients with gastrointestinal cancers (including
GC).
2. Discussion
Theprognosis ofmetastatic GC is still poor. To date, platinum
plus a fluoropyrimidine is approved as first-line of therapy
and second-line treatment with ramucirumab and taxane or
irinotecan is widely used in patients who experience disease
progression. The possibility of a third line of therapy is
generally considered in patients with good performance sta-
tus. Single-agent chemotherapy with docetaxel, paclitaxel, or
irinotecan as well as different combinations was investigated
in small phase II or retrospective studies in this GC patient
population [16–20]; however, no therapy is recommended
by internationally recognised treatment guidelines in GC
patients who have failed two previous lines of treatment.
This scenario could however change as three novel agents
with a different mechanism of action (apatinib, nivolumab,
and TAS-102) have shown a survival advantage for the first
time in recent randomized phase III trials which involved
advanced GC patients progressed after at least two previous
lines of therapy (Tables 1, 2, and 3 [6–8]). In particular, the
TAGS and ATTRACTION-2 trials enrolled about 25% and
40% of patients treated with ≥4 previous chemotherapy regi-
mens which compose a very heavily pretreated population of
patients with metastatic GC [6, 7].
Although the possible availability of active agents may
be a positive option in a very poor therapeutic scenario, the
results reportedwith apatinib, nivolumab, and TAS-102 in the
above studies raise some controversial issues.
First, all the three novel drugs have been tested against
a placebo. Although this methodological choice of study
type is theoretically supported by the absence of a specific
treatment suggested by guidelines, a very recent phase III trial
which compared avelumab (a human anti-PD-L1monoclonal
antibody) to the physician’s choice chemotherapy did not
show improvements in OS or PFS in third-line of therapy of
GC patients [16]. Similarly, the KEYNOTE-061 trial showed
that pembrolizumab (an anti PD-1) did not significantly
improve OS compared with paclitaxel as second-line therapy
[21]. All these data underline the importance of an active
control for the evaluation of novel agents. On the other hand,
other targeted agents (regorafenib and everolimus) tested
in phase III trials against placebo in the third-line setting
for this disease did not obtain any survival improvement
[22, 23].
A second limitation of the studies with apatinib,
nivolumab, and TAS-102 in third or further line of treatment
is related to the fact that the absolute survival gain (difference
between OS of experimental arm with the OS of placebo)
ranges from 1.2 to 2.1 months (Figure 1) and the absolute PFS
gain ranges from 0.16 to 0.8 months only (Figure 2). These
results suggest a limited clinical efficacy in terms of absolute
survival advantages.
A third limitation of the apatinib and ATTRACTION-2
studies is related to the patients enrolled in these trials. The
apatinib trial did not perform a double-blind randomization















































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1: Data of median overall survival (OS) of the experimental arm and placebo arm and delta OS difference between OS of the












Figure 2: Data of median progression-free survival (PFS) of the experimental arm and placebo arm and delta PFS difference between PFS of
the experimental arm and placebo arm.
and enrolled Chinese patients only [8].TheATTRACTION-2
(nivolumab) trial was conducted in Japan, South Korea, and
Taiwan centres and excludedWestern patients [6].The TAGS
was the only study that enrolled both Western and Asian
patients [7]. Thus, differences in the ethnicity of enrolled
patients should be considered in evaluating study results and
their transferability to the Caucasian population.
A fourth limitation of the analysed studies is related to
the poor information of data on quality of life: this outcome
is widely incorporated in phase III studies involving patients
with solid tumours and recently it has been demonstrated
to be an important endpoint also in gastric cancer patients
who have often symptoms related to the extension of disease
[24]. While apatinib, nivolumab, and TAS-102 obtained a
statistically significant increased tumour control rate as com-
pared to placebo (Table 2), Li et al. did not show significant
differences between apatinib or placebo at any time point
about the quality of life score [8], the ATTRACTION-2 did
not investigate the effects of nivolumab on the patient quality
of life [6], and quality of life data have not yet been reported
for the TAGS study [7], although the quality of life is very
important in GC [24].
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Figure 3: Pooled analysis according to previous ramucirumab.
Finally, another limitation when heavily pretreated
patients are investigated raises from the percentage and
type of previous lines of treatment. In particular, the
rate of patients treated with a ramucirumab-based therapy
may influence the outcome. Notably, the TAGS and the
ATTRACTION-2 study enrolled patients who progressed
on previous ramucirumab (about 30% in TAGS and 10% in
ATTRACTION-2). A pooled analysis according to previous
ramucirumab revealed that OS was significantly improved
with a greater extent in patients not previously treated with
ramucirumab (HR=0.66; 95%CI: 0.56-0.78; p<0.00001, I2: 0%
Figure 3) compared with patients treated with ramucirumab
(HR=0.71; 95%CI: 0.52-0.97; p=0.003; I2: 0%Figure 3).There-
fore, previous ramucirumab-based therapy increases slightly
the risk of death if compared with patients not previously
treated with ramucirumab. Apatinib, nivolumab, and TAS-
102 have been the first anticancer agents to gain a statistically
significant advantage in survival in heavily pretreated cohort
of patients with metastatic GC within phase III trials. Some
concerns have however to be raised on study characteris-
tics and results such as the absence of an active therapy
control arm, differences in patient baseline characteristics,
limited absolute advantage in survival results, and lack of
patient quality of life information. These concerns have
been reflected in the decisions taken by regulatory agencies
worldwide on the approval of these drugs for this indication.
Apatinib has been approved in China only and has obtained
anorphandrug designation inWestern countries. Nivolumab
has been approved in Japan [25] but not inWestern countries.
TAS-102 has been recently approved for this indication in
gastric cancer in the USA by FDA, and an application for
the same indication has been filed to the European Medicine
Agency (EMA).
As other neoplasms, GC is a heterogeneous disease in
terms of clinical and molecular features, also as a function
of its progression within time. In the near future, efforts
in the development and clinical trials of antiangiogenic,
immunoactivity, and classical cytotoxic cancer therapeutics
should be pursued and specifically addressed to the identi-
fication of predictive biomarkers to improve the selection of
ideal patient candidates in the various settings of the disease.
This approach in the era of precision oncology represents
the main route able to obtain more clinical benefits and real
breakthrough advancements with all available therapies.
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